Editor in Chief Dr KK Aggarwal, Padma Shri Awardee
No cold, cough medicines without prescription
RAJKOT: Jamnagar district collector, Ravi Shankar, on Monday has asked the medical shops in the district not to give give cold and cough medicines without prescriptions by doctors, in view of the increasing Covid-19 positive cases in the district.
“The cases have spiralled because patients don’t see doctors at initial stages. When they suffer from cold and cough, which are the initial symptoms of the disease, instead of going to the doctors, they buy medicines from the medical stores,” said Shankar. “If the patients see the doctors when they suffer from cold and cough, diagnosis at the initial stage can be done and the patients can get treatment at the beginning of Covid-19. At present, most of the Covid-19 patients get admitted to the hospital when they are at the last stage,” explained Shankar. “Hence, I urge all the medical stores and shops to not give medicines of cold and cough to the patients without the proper prescriptions from the doctors,” he said.
CMAAO Coronavirus Facts and Myth Buster: COVID Dermatology Update
With inputs from Dr Monica Vasudev
Update on COVID-19: IMA-CMAAO Webinar on “Dermatology Update and COVID-19”
18th June, 2020, 4-5pm,Participants: Dr KK Aggarwal, President CMAAO; Dr RV Asokan, Hony Secretary General IMA; Dr Ramesh K Datta, Hony Finance Secretary IMA; Dr Jayakrishnan Alapet; Dr Sanchita Sharma
,Faculty: Dr Anil Ganjoo, Senior Dermatologist, Gujranwala, Delhi
,The coronavirus has an affinity for the bronchial mucosal and the immune system. But the infection can also involve the cardiovascular system, liver and kidney.
,Skin involvement may either be a direct manifestation of the disease, such as skin rashes (primary cutaneous manifestations), or indirect manifestation due to the many processes associated with the disease (secondary cutaneous manifestations)....read more
World COVID Meter 21st July: India Number 3, 213 Countries Affected
Cases: 1M April 2, 2M April 15, 3M April 27, 4M May 8, 5M May 20, 6M May 30, 7M June 7, 8M June 15, 9M June 22, 10M June 29th, 11M July 4, 12M July 8, 13M July 13, 14M July 17
,Ground Zero: Wuhan - in live animal market or cafeteria for animal pathogens: 10th January; Total cases are based on RT PCR, 67% sensitivity
,Doubling time India 20 days, USA 33 days, Brazil 13 days, Russia 18 days, Spain 47 days, UK 35 days, Italy 55 days, France 49 days, Turkey 37 days
,Coronavirus Cases: 14,860,510,Deaths: 613,387,Deaths: 613,387,Recovered: 8,913,067....read more
The vast power of the Spirit
Om Poornamadah, “Om Poornamadah Poornamidam, Poornaat Poornamudachyate Poornasya Poornamaadaaya, Poornameva Avasihyate”,The whole is whole; if you take away the whole from the whole, the whole will still remain. (That is infinite, this is infinite, from the infinite, the infinite has come out. Having taken the infinite out of the infinite, the infinite alone remains).
,(In Vedanta “That” represents super consciousness, God or the Brahman and “This” the visible universe).
,Atman, which makes up our body, is 99.99% space and if we look at the rest, it is also nothing but space or void. This void or ‘akasha’ is what is called Brahman, God or consciousness and is a web of energized information. This web of information of inner space called inner consciousness is the Atman or the Soul. This is connected with the outer space in the universe having a similar web of energized information called the Spirit or Brahmand.
Video of The day
NGT campaign in COVID time
Healthcare News Monitor
The new facility offers conditioning of packaging materials in different chambers for varying temperatures up to -20oC
DHL Global Forwarding, the freight forwarding specialist of Deutsche Post DHL Group has opened its first temperature-controlled facility in India. Located in the cargo satellite building close to the airport in Hyderabad, the new facility offers conditioning of packaging materials in different chambers for varying temperatures up to -20°C, to meet the stringent needs of pharma shipments, informs a statement from the company.
“Hyderabad has a dominant position in the pharma industry in India, ranking first in the manufacturing of bulk drugs and third in formulations in the country. With an expected increase of 20 per cent in pharmaceutical exports annually, Hyderabad is often dubbed as the ‘Vaccine Hub of India’ with the country’s leading vaccine producers based in this city. The clinical trial sector in Hyderabad has also witnessed a steep rise with several prominent clinical trial companies housed here,” stated the company, giving a rationale for choosing Hyderabad as the location for its first temperature-controlled facility in India.
COVID-19 Vaccine India Updates: The Centre is expediting the process to give clearance to Serum Institute, Pune, which wants to take up the phase 3 trial of the Oxford vaccine before it starts mass-producing the vaccine. Also Read - COVID-19: Serum Institute to Begin Oxford Vaccine Trials on 5,000 Indian Volunteers by August End
Soon after the Oxford vaccine kindled some hope in the worldwide fights against COVID-19, Serum Institute of India chief executive officer Adar Poonawalla said that the company will apply for permission for phase 3 trials for the Oxford vaccine in India next week and will begin the study soon. Also Read - 'Fingers Crossed': Twitter Hopeful After First Trial of Oxford Vaccine Shows Promise, Netizens Celebrate With Memes
New Delhi [India], July 21 (ANI): The All India Institute of Medical Sciences (AIIMS), Delhi in collaboration with Union Health Ministry and NITI Aayog is all set to start a national programme called --"National Clinical Grandrounds on COVID-19" from Wednesday.
The idea is to get every doctor across the country to learn and share their best practices in the treatment of coronavirus patient as COVID-19 pandemic is an evolving situation, said Dr VK Paul, member (health) National Institution for Transforming India (NITI) Aayog.
The Indian Express
Most institutions which took part in the Indian Council of Medical Research’s (ICMR) trial on plasma therapy have found blood transfusion from recovered Covid-19 patients to those with moderately severe illness to be effective.
This is the only pan-India study on the topic,and institutions have submitted their findings to ICMR.
Out of 52 institutions participating in the ICMR PLACID trial, The Indian Express spoke with principal investigators of 36 institutions, of whom 24 said plasma therapy was effective.